

Drug impaired driving: screening and confirmation analysis on the road using HPLC-MS/MS on a mobile laboratory

Gianmarco Pezzuti^{1,3}, Flaminia Vincenti¹, Flavia Pagano², Ilenia Bracaglia^{1,2}, Gaia Di Francesco¹, Martina Croce^{1,2}, Francesco Bartolini¹, Manuel Sergi¹, Camilla Montesano¹, Stefano Marchetti³.



¹University of Rome "La Sapienza", Department of Chemistry, Rome, Italy ²University of Rome "La Sapienza", Department of Public health and Infectious diseases, Rome, Italy ³Forensic Lab Service S.r.l., Rome, Italy

FORENSICS

email: gianmarco.pezzuti@uniroma1.it



Introduction

Driving under the influence of drugs (DUID) is the cause of many accidents in Italy and in the world. Road control, together with prevention activities, are the most effective means of facing DUID. Article 187 of the c.d.s provides that stopped drivers carry out a screening analysis, a confirmation analysis and a medical examination assessing the alteration of the subject. Confirmatory analysis and associated medical examination are usually not performed on the street because they require specialized personnel and nonportable instrumentation (HPLC-MS or GC-MS). Normally the person, resulted positive to the screening test, is accompanied to the hospital to allow the execution of the confirmation analysis. This procedure usually takes a long time, which means that the medical examination (useful for ascertaining the state of alteration) is carried out even many hours after the moment of detention, resulting in a false result. In addition, the analytical result is also provided after days or weeks from the arrival of the sample, resulting in inevitable slowdowns in the closures of the practices. For these reasons, in 2019, a mobile laboratory was set up, equipped with equipment for screening analysis and an HPLC-MS for confirmatory analysis, allowing all the planned analyses to be carried out directly on site[1].



HPLC parameter:

Analysis workflow

■ B.Conc ■ A.Conc

For this purpose, oral fluid (OF) is considered a premium matrix for drug-of-abuse testing [2,3]. The main advantages of OF are the simplicity and noninvasiveness of sample collection. Similarly to blood, OF can reflect recent drug use appropriately, in fact substances can be detected in OF for short periods of time, typically up to 12–24 h after the assumption.

For confirmation test (second level) the saliva samples are analyzed using chromatographic methods coupled with mass spectrometry (HPLC-MS/MS). The developed method is characterized by a rapid and easy sample-prep and can detect and quantify 17 analytes in 15 minutes.







100 μL of the solution from disposable device 100μL MeOH solution containing ISs

30 sec vortex 10 min 14.000 rpm 4°C




HPLC-MS/MS Method

1.8 286.1 120 10

in to parameter.	100	Morphine	Morphine-D6	1 2	286.1	120	10	103	00	
Column: C18 50x2.1 ID mm – 5 μm	80	Νοιριπιε	WOI PHINE-DO	1.0	200.1	120	10	181	48	12
particles 100C	60	Codeine Amphetamine	Codeine-D6 Amphetamine-D5		300.1 136.1	120	10	165.1	64	12
Column Temperature: 40°C	%							153.1 91	62 27	12 12
Phase A: $H_20 + 0.1\%$ FA Phase B: Methanol + 0.1% FA	40					45	10	119	13	12
Injection volume: 2µL	20							165	53	12
Injection volume. 2µL	0 0.00 3.00 6.00 min 9.00 12.00 15.00	6-MAM	6-MAM-D6	3.9	328.0	140	10	211.2	38	12
	0 0.00 3.00 6.00 min 9.00 12.00 15.00	MDA	MDA-D5	4.1	180.2	50	10	133.1	25	12
							10	135.1	27	12
XIC of +MRM (59 pairs): 292.000/181.000 amu Expec	ted RT: 1.8 ID: IS MORFINA-D6 from Sample 7 (Cal 5) of curva e QC.wiff (Max. 1.4e5 cps.	Methamphetamine	Methamphetamine-D5	4.2	150.1	60	10	119.1	16	12
8.0e6 -]		·	·					91	29	12
7.5e8 -		BEG	BEG-D3	4.3	290.1	95	10	168.1 105	25 44	12 12
7.0e6 -		MDMA	MDMA-D5	4.5	194.2	65		163	18	12
							10	105	34	12
6.5e6 -		MDE	MDE-D6	5.1	208.2	62	10	163.1	29	12
6.0e6 -							10	135.1	25	12
5.5e6 - 5.0e6 -		Ketamine	No-IS	5.3	238.0	65	10	125	38	12
		MBDB	MBDB-D3	5.4	208.2			179.1	25	12
4.5e6						60	10	135.2 177	31 15	12 12
nitensity, cps		Cocaine	Cocaine-D3	6.0	304.2			182.2	27	12
<u>≇</u> 3.5e8 -						120	10	105.2	34	12
3.0e6 - 2.5e6 -		Cocaethylene	Cocaethylene-D3	6.8	318.1	100	10	196.1	28	12
							10	150	35	12
		Buprenorphine	Buprenorphine-D4	7.8	468.2	90	10	396.1	53	10
2.0e6 -								414.3	48 42	10
1.5e8		EDDP	EDDP-D3	8.0	278.1	120	10	234249.1	33	12 12
1.0e6							193.2	33	12	
5.0e5 -		THC	THC-D3	8.6	315.2	50	10	123.2	45	12
0.0	3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5 11.0	NA other desire	Mathadana DO	0.0	210.2	00		265.1	22	12
	Time, min	Methadone	Methadone-D9	8.9	310.2	80	10	223.1	30	12



In 2023, 2168 screening tests were carried out in 92 days. About 9% of the screening is positive for at least one substance and confirmed by LC-MS analysis. Thanks to this project, it was possible to provide an important contribution by analyzing data regarding drug consumption in Italy and identifying which substances are more used.



■ THC ■ COCAINE ■ OPIOIDS ■ AMPHETAMINE/M.AMPHETAMINE

Conclusion

As innovative and unique feature of the presented study, all the steps of the DUID control take place on a mobile Lab, from screening to confirmation and quantitative analysis. Thanks to this project comprehensive and certified response is possible and is provided in about 30 min. The HPLC-MS/MS method was validated according to international guidelines showing very good value of precision, accuracy, matrix effect, LOD and LOQ. This project is still active thanks to several national collaborations. International collaboration will be taking place in the next period.

References

1. Ariana Soledad Poetto et al. Forensic Science International 355 (2024) 111929.

2. European Monitoring Center for Drugs and Drug Addiction (EMCDDA), Publications Office of the European Union (2021) 3. A.M. Projektvorstellung. The "Driving under the Influence of Drugs, Alcohol and Medicines" (DRUID) project of the European Commission]. Dtsch Med Wochenschr. (2008) 133- 2: 45-46.